{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T03:12:20Z","timestamp":1774840340258,"version":"3.50.1"},"reference-count":61,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T00:00:00Z","timestamp":1544745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Cancer is a disease that affects and kills millions of people worldwide. Breast cancer, especially, has a high incidence and mortality, and is challenging to treat. Due to its high impact on the health sector, oncological therapy is the subject of an intense and very expensive research. To improve this therapy and reduce its costs, strategies such as drug repurposing and drug combinations have been extensively studied. Drug repurposing means giving new usefulness to drugs which are approved for the therapy of various diseases, but, in this case, are not approved for cancer therapy. On the other hand, the purpose of combining drugs is that the response that is obtained is more advantageous than the response obtained by the single drugs. Using drugs with potential to be repurposed, combined with 5-fluorouracil, the aim of this project was to investigate whether this combination led to therapeutic benefits, comparing with the isolated drugs. We started with a screening of the most promising drugs, with verapamil and itraconazole being chosen. Several cellular viability studies, cell death and proliferation studies, mainly in MCF-7 cells (Michigan Cancer Foundation-7, human breast adenocarcinoma cells) were performed. Studies were also carried out to understand the effect of the drugs at the level of possible therapeutic resistance, evaluating the epithelial-mesenchymal transition. Combining all the results, the conclusion is that the combination of verapamil and itraconazole with 5-fluorouracil had benefits, mainly by decreasing cell viability and proliferation. Furthermore, the combination of itraconazole and 5-fluorouracil seemed to be the most effective, being an interesting focus in future studies.<\/jats:p>","DOI":"10.3390\/biom8040175","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T12:11:08Z","timestamp":1544789468000},"page":"175","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Study of New Therapeutic Strategies to Combat Breast Cancer Using Drug Combinations"],"prefix":"10.3390","volume":"8","author":[{"given":"Ana","family":"Correia","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"},{"name":"Department of Molecular Pathology and Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"given":"Dany","family":"Silva","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"given":"Alexandra","family":"Correia","sequence":"additional","affiliation":[{"name":"i3S, Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"},{"name":"Department of Imuno-Physiology and Pharmacology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"},{"name":"Institute of Molecular and Cell Biology (IBMC) of the University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7007-306X","authenticated-orcid":false,"given":"Manuel","family":"Vilanova","sequence":"additional","affiliation":[{"name":"i3S, Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"},{"name":"Department of Imuno-Physiology and Pharmacology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"},{"name":"Institute of Molecular and Cell Biology (IBMC) of the University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"}]},{"given":"F\u00e1tima","family":"G\u00e4rtner","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology and Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"},{"name":"i3S, Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Rua J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"},{"name":"Department of Molecular Pathology and Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"},{"name":"i3S, Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Rua J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2018,12,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1001\/jama.308.17.1813-b","article-title":"Harrison\u2019s Principles of Internal Medicine","volume":"308","author":"Malani","year":"2012","journal-title":"JAMA"},{"key":"ref_2","unstructured":"Cancer Research UK (2018, August 08). Worldwide Cancer Statistics. Available online: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/worldwide-cancer#heading-One."},{"key":"ref_3","unstructured":"Cancer Therapy Advisor (2018, March 21). Breast Cancer (Invasive) Treatment Regimens. Available online: https:\/\/www.cancertherapyadvisor.com\/breast-cancer\/breast-cancer-invasive-treatment-regimens\/article\/218154\/."},{"key":"ref_4","unstructured":"Green, R.J., and Harris, N.D. (2008). Pathology and Therapeutics for Pharmacists, Pharmaceutical Press. [3rd ed.]."},{"key":"ref_5","first-page":"1101","article-title":"Cancer stem cells: Implications for cancer therapy","volume":"28","author":"Dawood","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fmed.2017.00211","article-title":"Drug Repurposing for the Treatment of Acute Myeloid Leukemia","volume":"4","author":"Andresen","year":"2017","journal-title":"Front. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fonc.2017.00273","article-title":"Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs as Cancer Therapeutics","volume":"7","author":"Hernandez","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3332\/ecancer.2014.485","article-title":"The repurposing drugs in oncology (ReDO) project","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12967-016-1031-5","article-title":"Repurposing of approved cardiovascular drugs","volume":"14","author":"Ishida","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2017.06.007","article-title":"Repurposing drugs in oncology: Next steps","volume":"3","author":"Verbaanderd","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","article-title":"Drug repurposing in oncology\u2014Patient and health systems opportunities","volume":"12","author":"Bertolini","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","unstructured":"ClinicalTrials.gov (2018, May 25). A Phase III Randomized Trial of Metformin vs. Placebo in Early Stage Breast Cancer, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01101438."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: Current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nbt.3834","article-title":"Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions","volume":"35","author":"Han","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_16","unstructured":"National Cancer Institute (2018, August 04). Combining Therapies to Improve Outcomes, Available online: https:\/\/www.cancer.gov\/about-nci\/budget\/plan\/treating\/combining-therapies."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lu, D.-Y. (2015). Drug combinations. Personalized Cancer Chemotherapy, Woodhead Publishing.","DOI":"10.1016\/B978-0-08-100346-6.00006-6"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrc2193","article-title":"Modelling breast cancer: One size does not fit all","volume":"7","author":"Rosen","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7150\/jca.4925","article-title":"Treating breast cancer in the 21st century: Emerging biological therapies","volume":"4","author":"Tinoco","year":"2013","journal-title":"J. Cancer"},{"key":"ref_21","unstructured":"American Cancer Society (2018, August 20). Treatment of Breast Cancer by Stage. Available online: https:\/\/www.cancer.org\/cancer\/breast-cancer\/treatment\/treatment-of-breast-cancer-by-stage.html."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.12688\/f1000research.4340.1","article-title":"Current treatment of early breast cancer: Adjuvant and neoadjuvant therapy","volume":"3","author":"Miller","year":"2014","journal-title":"F1000Research"},{"key":"ref_23","unstructured":"Medscape (2018, August 06). Breast Cancer Treatment & Management. Available online: https:\/\/emedicine.medscape.com\/article\/1947145-treatment#showall."},{"key":"ref_24","unstructured":"Anticancer Fund (2018, August 07). Repurposing Non-Cancer Drugs for Breast Cancer? An Emerging Opportunity. Available online: https:\/\/www.anticancerfund.org\/en\/repurposing-non-cancer-drugs-breast-cancer-emerging-opportunity."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"ed82","DOI":"10.3332\/ecancer.2018.ed82","article-title":"Propranolol and breast cancer\u2014A work in progress","volume":"12","author":"Pantziarka","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.ijgo.2015.03.015","article-title":"A historic and scientific review of breast cancer: The next global healthcare challenge","volume":"131","author":"Becker","year":"2015","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: Mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13046-017-0526-0","article-title":"Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells","volume":"36","author":"Hu","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.3892\/ol.2017.6569","article-title":"Repurposing itraconazole for the treatment of cancer","volume":"14","author":"Pounds","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3892\/ijo.2016.3512","article-title":"Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells","volume":"49","author":"Zhao","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0143-4160(85)90021-1","article-title":"The calcium channel blocker verapamil and cancer chemotherapy","volume":"6","author":"Simpson","year":"1985","journal-title":"Cell Calcium"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00003495-198938010-00003","article-title":"Verapamil: An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension","volume":"38","author":"McTavish","year":"1989","journal-title":"Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1016\/j.bbamem.2015.03.034","article-title":"Targeting ion channels for cancer therapy by repurposing the approved drugs","volume":"1848","author":"Kale","year":"2015","journal-title":"Biochim. Et Biophys. Acta (BBA) Biomembr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-glycoprotein in pharmacokinetics: Clinical implications","volume":"42","author":"Lin","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_35","first-page":"2413","article-title":"Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse","volume":"52","author":"Taylor","year":"1992","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/0006-2952(94)90550-9","article-title":"Potentiation of tamoxifen activity by verapamil in a human breast cancer cell line","volume":"47","author":"Gupta","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jamainternmed.2013.9071","article-title":"Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years","volume":"173","author":"Li","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_38","unstructured":"UniProt (2018, August 22). UniProtKB-Q16850 (CP51A_HUMAN). Available online: https:\/\/www.uniprot.org\/uniprot\/Q16850."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"654","DOI":"10.7150\/ijbs.9224","article-title":"Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs","volume":"10","author":"Shim","year":"2014","journal-title":"Int. J. Boil. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canlet.2016.10.034","article-title":"Anti-proliferation of breast cancer cells with itraconazole: Hedgehog pathway inhibition induces apoptosis and autophagic cell death","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_41","first-page":"18","article-title":"Timing your apoptosis assays","volume":"16","author":"Sundquist","year":"2006","journal-title":"Cell Notes"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF03044961","article-title":"Morphologic criteria and detection of apoptosis","volume":"24","author":"Saraste","year":"1999","journal-title":"Herz"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.1038\/sj.onc.1209091","article-title":"Epithelial\u2013mesenchymal transition in development and cancer: Role of phosphatidylinositol 3\u2032 kinase\/AKT pathways","volume":"24","author":"Larue","year":"2005","journal-title":"Oncogene"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3892\/ol.2015.3136","article-title":"Acquisition of 5-fluorouracil resistance induces epithelial-mesenchymal transitions through the Hedgehog signaling pathway in HCT-8 colon cancer cells","volume":"9","author":"Liu","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5487\/TR.2015.31.2.151","article-title":"Epithelial-mesenchymal Transition is Associated with Acquired Resistance to 5-Fluorocuracil in HT-29 Colon Cancer Cells","volume":"31","author":"Kim","year":"2015","journal-title":"Toxicol. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2011.11.142","article-title":"Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells","volume":"417","author":"Zhang","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1007\/s00018-008-8281-1","article-title":"The cell-cell adhesion molecule E-cadherin","volume":"65","author":"Berx","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"662","DOI":"10.14202\/vetworld.2017.662-666","article-title":"Changes in histopathology and cytokeratin AE1\/AE3 expression in skin graft with different time on Indonesian local cats","volume":"10","author":"Erwin","year":"2017","journal-title":"Vet. World"},{"key":"ref_49","unstructured":"ProPath (2018, August 26). Cytokeratin AE1\/AE3. Available online: http:\/\/propath.org\/companies\/press-clippings\/26-newsletters\/271-cytokeratin-ae1-ae3-november-2003."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","article-title":"Vimentin in cancer and its potential as a molecular target for cancer therapy","volume":"68","author":"Satelli","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/nprot.2009.152","article-title":"The morphological and molecular features of the epithelial-to-mesenchymal transition","volume":"4","author":"Peinado","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"85021","DOI":"10.18632\/oncotarget.13116","article-title":"EGF induces epithelial-mesenchymal transition through phospho-Smad2\/3-Snail signaling pathway in breast cancer cells","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8265","DOI":"10.1038\/s41598-017-08047-1","article-title":"An epithelial-to-mesenchymal transition-inducing potential of granulocyte macrophage colony-stimulating factor in colon cancer","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_54","unstructured":"GraphPad Software (2018, August 23). 50% of What? How Exactly are IC50 and EC50 Defined?. Available online: https:\/\/www.graphpad.com\/support\/faq\/50-of-what-how-exactly-are-ic50-and-ec50-defined\/."},{"key":"ref_55","unstructured":"GraphPad Software (2018, August 23). Pros and Cons of Normalizing the Data. Available online: https:\/\/www.graphpad.com\/guides\/prism\/7\/curve-fitting\/index.htm?reg_pros_and_cons_of_normalizing.htm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/ijc.21938","article-title":"Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: Relationship with cell cycle changes and apoptosis, and identification of novel targets of p53","volume":"119","author":"Ballestar","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2217\/fon-2017-0607","article-title":"Improving combination cancer therapy: The CombiPlex development platform","volume":"14","author":"Tolcher","year":"2018","journal-title":"Future Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/btm2.10082","article-title":"Schedule dependent synergy of gemcitabine and doxorubicin: Improvement of in vitro efficacy and lack of in vitro-in vivo correlation","volume":"3","author":"Vogus","year":"2018","journal-title":"Bioeng. Transl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2017.08.016","article-title":"A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer","volume":"267","author":"Vogus","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1021\/acs.molpharmaceut.7b00219","article-title":"A nano-in-nano polymer-dendrimer nanoparticle-based nanosystem for controlled multidrug delivery","volume":"14","author":"Zhao","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"9210","DOI":"10.1021\/acsomega.8b00949","article-title":"Multifunctional nanosystem for targeted and controlled delivery of multiple chemotherapeutic agents for the treatment of drug-resistant breast cancer","volume":"3","author":"Lou","year":"2018","journal-title":"ACS Omega"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/8\/4\/175\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:34:08Z","timestamp":1760196848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/8\/4\/175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,14]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["biom8040175"],"URL":"https:\/\/doi.org\/10.3390\/biom8040175","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,14]]}}}